Advertisement

Hereditary Cancer Gene Variants in Hispanic Men With a Personal or Family History of Prostate Cancer

Published:January 14, 2022DOI:https://doi.org/10.1016/j.clgc.2022.01.008

      Abstract

      Background

      Mutations in several common hereditary cancer genes are associated with prostate cancer, but there is limited information on the prevalence of these mutations in Hispanic men.

      Materials and Methods

      We selected men at high risk for genetic mutations from 1515 Hispanic men enrolled in the San Antonio Biomarkers of Risk for prostate cancer (SABOR) cohort. Inclusion criteria included men with a diagnosis of prostate cancer or a first-degree family history of prostate cancer. We performed germline genetic testing using the Color Genomics platform, sequencing 30 genes associated with hereditary cancer risk. Additionally, we assessed ancestral informative markers to determine the admixture of the ethnically unique cohort.

      Results

      Of the 275 subjects who met selection criteria, 263 patients had sufficient samples for sequencing. We identified 3.8% of patients (10 of 263) with a pathogenic or likely pathogenic mutation in the 30 genes tested, of whom 70% would not have met established criteria for genetic testing. Six of these mutations were in BRCA1/2 or ATM. There was a significant inverse association between the percentage of Native American ancestry and the risk of prostate cancer, OR 0.11 (95% CI 0.02-0.76, P = .025).

      Conclusion

      Hispanic men with either a personal or family history of prostate cancer carry mutations in hereditary cancer genes at a significant rate, on par with non–Hispanic counterparts with similar risk factors.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics.
        CA Cancer J Clin. 2019; 69: 7-34
        • Pritchard C.C.
        • Mateo J.
        • Walsh M.F.
        Inherited DNA-repair gene mutations in men with metastatic prostate cancer.
        N Engl J Med. 2016; 375: 443-453
        • Ewing C.M.
        • Ray A.M.
        • Lange E.M.
        Germline mutations in HOXB13 and prostate-cancer risk.
        N Engl J Med. 2012; 366: 141-149
        • Kote-Jarai Z.
        • Leongamornlert D.
        • Saunders E.
        BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
        Br J Cancer. 2011; 105: 1230-1234
        • Leongamornlert D.
        • Saunders E.
        • Dadaev T.
        Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.
        Br J Cancer. 2014; 110: 1663-1672
        • Nicolosi P.
        • Ledet E.
        • Yang S.
        Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines.
        JAMA Oncol. 2019; 5: 523-528
        • The Cancer Genome Atlas Research Network.
        The molecular taxonomy of primary prostate cancer.
        Cell. 2015; 163: 1011-1025
        • Spratt D.E.
        • Chan T.
        • Waldron L.
        Racial/ethnic disparities in genomic sequencing.
        JAMA Oncol. 2016; 2: 1070-1074
        • Hazuda H.P.
        • Comeaux P.J.
        • Stern M.P.
        • Haffner S.M.
        • Eifler C.W.
        • Rosenthal MJAJoE
        A comparison of three indicators for identifying Mexican Americans in epidemiologic research, methodological findings from the San Antonio heart study.
        Am J Epidemiol. 1986; 123: 96-112
        • Homburger J.R.
        • Neben C.L.
        • Mishne G.
        • Zhou A.Y.
        • Kathiresan S.
        • Khera A.V.
        Low coverage whole genome sequencing enables accurate assessment of common variants and calculation of genome-wide polygenic scores.
        Genome Med. 2019; 11: 74
        • Auton A.
        • Abecasis G.R.
        • Altshuler D.M.
        A global reference for human genetic variation.
        Nature. 2015; 526: 68-74
        • Jorsboe E.
        • Hanghoj K.
        • Albrechtsen A.
        fastNGSadmix: admixture proportions and principal component analysis of a single NGS sample.
        Bioinformatics. 2017; 33: 3148-3150
      1. National Comprehensive Cancer Network. Genetic/Familial high-risk assessment: breast, ovarian, and pancreatic (Version 1.2020). 2020, Accessed from: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (accessed 4/2020).

      2. Giri V.N., Obeid E., Gross L., Inherited mutations in men undergoing multigene panel testing for prostate cancer: emerging implications for personalized prostate cancer genetic evaluation. JCO Precis Oncol2017;1: 1-17.

        • Lek M.
        • Karczewski K.J.
        • Minikel E.V.
        Analysis of protein-coding genetic variation in 60,706 humans.
        Nature. 2016; 536: 285-291
        • Manickam K.
        • Buchanan A.H.
        • Schwartz M.L.B.
        Exome sequencing-based screening for BRCA1/2 expected pathogenic variants among adult biobank participants.
        JAMA Netw Open. 2018; 1e182140
        • Bancroft E.K.
        • Page E.C.
        • Castro E.
        Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
        Eur Urol. 2014; 66: 489-499
        • Na R.
        • Zheng S.L.
        • Han M.
        Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death.
        Eur Urol. 2017; 71: 740-747
        • Mateo J.
        • Carreira S.
        • Sandhu S.
        DNA-repair defects and olaparib in metastatic prostate cancer.
        N Engl J Med. 2015; 373: 1697-1708
        • Mateo J.
        • Porta N.
        • McGovern U.B.
        TOPARP-B: A phase II randomized trial of the poly (ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.
        American Society of Clinical Oncology, ASCO Annual Meeting 20192019
        • Villarreal-Garza C.
        • Alvarez-Gomez R.M.
        • Perez-Plasencia C.
        Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
        Cancer. 2015; 121: 372-378
        • Villarreal-Garza C.
        • Weitzel J.N.
        • Llacuachaqui M.
        The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.
        Breast Cancer Res Treat. 2015; 150: 389-394
        • Weitzel J.N.
        • Lagos V.
        • Blazer K.R.
        Prevalence of BRCA mutations and founder effect in high-risk Hispanic families.
        Cancer Epidemiol Biomarkers Prev. 2005; 14: 1666-1671
        • Rebbeck T.R.
        • Friebel T.M.
        • Friedman E.
        Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
        Hum Mutat. 2018; 39: 593-620
      3. National comprehensive cancer network. Genetic/Familial high risk assessment: colorectal (Version 2.2019). 2020, Accessed from: https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (accessed 4/2020).

        • Ikonen T.
        • Matikainen M.
        • Mononen N.
        Association of E-cadherin germ-line alterations with prostate cancer.
        Clin Cancer Res. 2001; 7: 3465-3471